ici 118551 and Angiogenesis, Pathologic

ici 118551 has been researched along with Angiogenesis, Pathologic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguirre, DT; Albiñana, V; Botella, LM; Cuesta, AM; de Las Heras, KVG; de Rojas-P, I; Gallardo-Vara, E; Recio-Poveda, L1
McDonald, DM1

Other Studies

2 other study(ies) available for ici 118551 and Angiogenesis, Pathologic

ArticleYear
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.
    Scientific reports, 2019, 07-11, Volume: 9, Issue:1

    Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Nucleus; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Propanolamines; Signal Transduction; Tumor Cells, Cultured; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein

2019
Angiogenesis and remodeling of airway vasculature in chronic inflammation.
    American journal of respiratory and critical care medicine, 2001, Nov-15, Volume: 164, Issue:10 Pt 2

    Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Angiopoietin-1; Animals; Asthma; Bronchitis; Bronchodilator Agents; Capillary Permeability; Chronic Disease; Disease Models, Animal; Endothelial Growth Factors; Endothelium; Humans; Inflammation; Lung; Lymphokines; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Microcirculation; Nebulizers and Vaporizers; Neovascularization, Pathologic; Pneumonia, Mycoplasma; Propanolamines; Rats; Rats, Wistar; Research; Respiratory Mucosa; Salmeterol Xinafoate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001